0001193125-16-756511 Sample Contracts

CREDIT AGREEMENT dated as of August 31, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger

Credit Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

• Contract Type
  Credit Agreement
• Filed
  November 2nd, 2016
• Company
  Myriad Genetics Inc
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  New York

CREDIT AGREEMENT (this “Agreement”) dated as of August 31, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

INDEMNIFICATION AGREEMENT

Indemnification Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

• Contract Type
  Indemnification Agreement
• Filed
  November 2nd, 2016
• Company
  Myriad Genetics Inc
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  Delaware

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this 26th day of September, 2016, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and Virginia C. Drosos (“Agent”).

MYRIAD GENETICS, INC. Executive Retention Agreement

Executive Retention Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah

• Contract Type
  Executive Retention Agreement
• Filed
  November 2nd, 2016
• Company
  Myriad Genetics Inc
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  Utah

THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Virginia C. Drosos (the “Executive”), is made as of September 26, 2016 (the “Effective Date”).

AGREEMENT AND PLAN OF MERGER among: MYRIAD GENETICS, INC. a Delaware corporation; MYRIAD MERGER SUB, INC., a Delaware corporation; ASSUREX HEALTH, INC., a Delaware corporation; and FORTIS ADVISORS LLC, as the Securityholders’ Agent Dated as of August...

Agreement and Plan of Merger • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

• Contract Type
  Agreement and Plan of Merger
• Filed
  November 2nd, 2016
• Company
  Myriad Genetics Inc
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 3, 2016, by and among MYRIAD GENETICS, INC., a Delaware corporation (“Parent”); MYRIAD MERGER SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”); ASSUREX HEALTH, INC., a Delaware corporation (the “Company”); and FORTIS ADVISORS LLC, a Delaware limited liability company, as the Securityholders’ Agent (as defined in Section 11.1(a)). Certain capitalized terms used in this Agreement are defined in Exhibit A.